Spots Global Cancer Trial Database for anaplastic large cell lymphoma
Every month we try and update this database with for anaplastic large cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | NCT03534180 | Anaplastic Larg... Recurrent Matur... Refractory Matu... | Laboratory Biom... Romidepsin Venetoclax | 18 Years - | City of Hope Medical Center | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | NCT01657331 | Hodgkin Lymphom... Anaplastic Larg... | Brentuximab Ved... Bendamustine Neulasta | 18 Years - | Columbia University | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | NCT00117988 | Anaplastic Larg... Recurrent Adult... Recurrent Mantl... | tanespimycin | 16 Years - | National Cancer Institute (NCI) | |
| Vinorelbine for Recurrent ALCL-2017 | NCT03443128 | Anaplastic Larg... Vinorelbine | Vinorelbine | - 18 Years | Children's Cancer Group, China | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | NCT00602693 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | NCT00787527 | Lymphoma | Zolinza (vorino... Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | NCT00082017 | Lymphoma, Large... Lymphoma, T-Cel... | UCN-01 (7-hydro... | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00073918 | Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | cyclophosphamid... etoposide iodine I 131 to... quality-of-life... peripheral bloo... | 18 Years - 60 Years | Fred Hutchinson Cancer Center | |
| Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00110006 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose... | 18 Years - | Case Comprehensive Cancer Center | |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | NCT01686165 | Anaplastic Larg... Recurrent Adult... Recurrent Mantl... | belinostat rituximab yttrium Y 90 ib... | 18 Years - | University of Arizona | |
| A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | NCT02487316 | Systemic Anapla... | crizotinib | 18 Years - 65 Years | Peking University | |
| Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | NCT00058019 | Anaplastic Larg... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Mantl... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | NCT03905135 | Peripheral T-ce... Mycosis Fungoid... Sezary Syndrome Anaplastic Larg... | rhIL-15 rhIL-15 Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | NCT00078949 | Lymphoma | rituximab cisplatin cytarabine dexamethasone gemcitabine hyd... | 16 Years - 65 Years | Canadian Cancer Trials Group | |
| Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | NCT00851552 | Lymphoma | rituximab bortezomib pegylated lipos... gene expression... polymerase chai... polymorphism an... proteomic profi... flow cytometry laboratory biom... | 18 Years - | Roswell Park Cancer Institute | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | NCT00058019 | Anaplastic Larg... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Mantl... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse | NCT00069966 | Lymphoma | filgrastim rituximab cisplatin cytarabine methylprednisol... pixantrone dima... autologous bone... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Vinorelbine for Recurrent ACLC | NCT03397953 | Anaplastic Larg... Vinorelbine | Vinorelbine | - 18 Years | Children's Cancer Group, China | |
| MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | NCT00298467 | Lymphoma, Large... | MDX-060 | 12 Years - | Bristol-Myers Squibb | |
| Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein | NCT00048880 | Neoplasms | HeFi-1 Monoclon... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00073957 | Lymphoma | rituximab cytarabine liposomal cytar... yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | NCT00006125 | Lymphoma | doxorubicin hyd... topotecan hydro... | - | Alliance for Clinical Trials in Oncology | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | NCT03534180 | Anaplastic Larg... Recurrent Matur... Refractory Matu... | Laboratory Biom... Romidepsin Venetoclax | 18 Years - | City of Hope Medical Center | |
| Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma | NCT00079261 | Lymphoma Small Intestine... | CHOP regimen cyclophosphamid... doxorubicin hyd... gemcitabine hyd... prednisone vincristine sul... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | NCT01793233 | Anaplastic Larg... Burkitt Lymphom... Diffuse Large B... Hodgkin Lymphom... Lymphoma | Laboratory Biom... Questionnaire A... | - 29 Years | Children's Oncology Group | |
| Vinorelbine for Recurrent ACLC | NCT03397953 | Anaplastic Larg... Vinorelbine | Vinorelbine | - 18 Years | Children's Cancer Group, China | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma | NCT00059839 | Lymphoma | doxorubicin hyd... mercaptopurine methotrexate prednisone vinblastine sul... vincristine sul... | - 20 Years | Children's Oncology Group | |
| Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | NCT00278382 | Anaplastic Larg... Recurrent Adult... Recurrent Mantl... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00004112 | Lymphoma | rituximab CHOP regimen cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 19 Years - 120 Years | University of Nebraska | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | NCT03598998 | Anaplastic Larg... Nodal Periphera... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Folli... Recurrent Hepat... Recurrent Matur... Recurrent Monom... Recurrent Mycos... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Foll... Refractory Hepa... Refractory Matu... Refractory Myco... Refractory Peri... Subcutaneous Pa... | Pembrolizumab Pralatrexate | 18 Years - | City of Hope Medical Center | |
| Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00110006 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose... | 18 Years - | Case Comprehensive Cancer Center | |
| Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | NCT00726700 | Lymphoma | pegfilgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 61 Years - 80 Years | Universität des Saarlandes | |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | NCT01943682 | Acute Myeloid L... Acute Lymphobla... Burkitt Lymphom... Diffuse Large C... Gray Zone Lymph... Lymphoblastic L... Anaplastic Larg... Hodgkin Lymphom... | CPX-351 | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma | NCT00354107 | Anaplastic Larg... Recurrent Child... | monoclonal anti... therapeutic hyd... ifosfamide carboplatin etoposide methotrexate cytarabine pharmacological... laboratory biom... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | NCT00720135 | Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Small Intestine... Splenic Margina... Testicular Lymp... Waldenstrom Mac... | DI-Leu16-IL2 im... rituximab flow cytometry immunohistochem... pharmacological... laboratory biom... enzyme-linked i... reverse transcr... | 18 Years - 65 Years | City of Hope Medical Center | |
| Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | NCT00004132 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera... | 12 Years - 65 Years | National Cancer Institute (NCI) | |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | NCT03534180 | Anaplastic Larg... Recurrent Matur... Refractory Matu... | Laboratory Biom... Romidepsin Venetoclax | 18 Years - | City of Hope Medical Center | |
| S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma | NCT00070018 | Lymphoma | rituximab Cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera... Yttrium-90 ibri... Indium-111 ibri... | 18 Years - | SWOG Cancer Research Network | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma | NCT00109928 | Lymphoma | cisplatin etoposide gemcitabine methylprednisol... | 18 Years - | SWOG Cancer Research Network | |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | NCT03905135 | Peripheral T-ce... Mycosis Fungoid... Sezary Syndrome Anaplastic Larg... | rhIL-15 rhIL-15 Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma | NCT00003215 | Lymphoma | filgrastim CHOP regimen cyclophosphamid... cytarabine doxorubicin hyd... etoposide leucovorin calc... melphalan methotrexate methylprednisol... mitoxantrone hy... prednisone therapeutic hyd... vincristine sul... bone marrow abl... peripheral bloo... radiation thera... | 18 Years - 60 Years | Swiss Group for Clinical Cancer Research | |
| Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma | NCT00003741 | Lymphoma | monoclonal anti... | 18 Years - | National Cancer Institute (NCI) | |
| UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | NCT00082017 | Lymphoma, Large... Lymphoma, T-Cel... | UCN-01 (7-hydro... | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | NCT01793233 | Anaplastic Larg... Burkitt Lymphom... Diffuse Large B... Hodgkin Lymphom... Lymphoma | Laboratory Biom... Questionnaire A... | - 29 Years | Children's Oncology Group | |
| MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | NCT00298467 | Lymphoma, Large... | MDX-060 | 12 Years - | Bristol-Myers Squibb | |
| Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment | NCT00014209 | Lymphoma | cisplatin dexamethasone gemcitabine hyd... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | NCT03205891 | Malignant Neopl... Classical Hodgk... Anaplastic Larg... CD30+ Periphera... | Brentuximab Ved... TAK228 Glucose Monitor | 18 Years - | M.D. Anderson Cancer Center | |
| Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma | NCT00079261 | Lymphoma Small Intestine... | CHOP regimen cyclophosphamid... doxorubicin hyd... gemcitabine hyd... prednisone vincristine sul... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | NCT01998035 | Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Romidepsin Oral 5-Azacitid... | 18 Years - | Columbia University | |
| Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma | NCT00059839 | Lymphoma | doxorubicin hyd... mercaptopurine methotrexate prednisone vinblastine sul... vincristine sul... | - 20 Years | Children's Oncology Group | |
| Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma | NCT00059839 | Lymphoma | doxorubicin hyd... mercaptopurine methotrexate prednisone vinblastine sul... vincristine sul... | - 20 Years | Children's Oncology Group | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein | NCT00048880 | Neoplasms | HeFi-1 Monoclon... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | NCT01606878 | Childhood Solid... Recurrent Child... Recurrent Neuro... | Crizotinib Cyclophosphamid... Dexrazoxane Hyd... Doxorubicin Hyd... Laboratory Biom... Pharmacological... Questionnaire A... Topotecan Hydro... Vincristine Sul... | 13 Months - 21 Years | Children's Oncology Group | |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | NCT00006125 | Lymphoma | doxorubicin hyd... topotecan hydro... | - | Alliance for Clinical Trials in Oncology | |
| Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00278408 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera... | 18 Years - 60 Years | German High-Grade Non-Hodgkin's Lymphoma Study Group | |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | NCT03049449 | Lymphoma, Large... Enteropathy-Ass... Lymphoma, Large... Lymphoma, Extra... Lymphoma, T-Cel... | Anti-Tumor Necr... Cyclophosphamid... Fludarabine | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas | NCT03383965 | Hodgkin Lymphom... Anaplastic Larg... | ICAR30 T cells | 2 Years - 80 Years | Immune Cell, Inc. | |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | NCT00001337 | Diffuse Large B... Primary Mediast... Burkitt Lymphom... Anaplastic Larg... Gray Zone Lymph... | EPOCH Rituximab | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | NCT03049449 | Lymphoma, Large... Enteropathy-Ass... Lymphoma, Large... Lymphoma, Extra... Lymphoma, T-Cel... | Anti-Tumor Necr... Cyclophosphamid... Fludarabine | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | NCT01998035 | Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Romidepsin Oral 5-Azacitid... | 18 Years - | Columbia University | |
| Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | NCT00720135 | Anaplastic Larg... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Small Intestine... Splenic Margina... Testicular Lymp... Waldenstrom Mac... | DI-Leu16-IL2 im... rituximab flow cytometry immunohistochem... pharmacological... laboratory biom... enzyme-linked i... reverse transcr... | 18 Years - 65 Years | City of Hope Medical Center | |
| Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00278408 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera... | 18 Years - 60 Years | German High-Grade Non-Hodgkin's Lymphoma Study Group | |
| S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | NCT00016094 | Anaplastic Larg... Recurrent Adult... Recurrent Adult... Recurrent Mantl... | bevacizumab laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma | NCT00606645 | Hodgkin Lymphom... Anaplastic Larg... | XmAb2513 | 18 Years - | Xencor, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
